Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monthly Recombinant Factor XIII (Catridecacog) Prophylaxis in Congenital FXIII Deficiency
2006-003148-51Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of catridecacog in congenital factor XIII deficiency and Congenital deficiency of other clotting factors, sponsored by Novo Nordisk. Primary endpoint: Rate of bleeding episodes requiring treatment during rFXIII treatment period. Started May 2008; status: completed.
02
Drugs
catridecacog
03
Conditions
congenital factor XIII deficiencyCongenital deficiency of other clotting factors
Beyond the preview
Go deeper on 2006-003148-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003148-51.